Emerging evidence suggests that Sildigra 250 Mg may have neuroprotective effects and could potentially benefit individuals with neurodegenerative diseases such as Alzheimer's and Parkinson's. Studies have shown that PDE5 inhibitors like Sildigra 250 Mg can increase levels of cyclic guano sine monophosphate (camp) in the brain, which plays a role in neuronal signalling and synaptic plasticity. While further research is needed, these findings offer promising avenues for exploring Sildigra 250 Mg's potential in neurological disorders. https://www.flatmeds.com/product/sildigra-250-mg/